A man from the world’s largest known Alzheimer’s family should have lost his memory by his late 40s. Every other carrier of the PSEN1-E280A mutation in his Colombian kindred, a sprawling extended family of roughly 6,000 people traced across generations, follows a grim script: cognitive decline begins around age 44, dementia sets in by 50, and death follows within a decade. But this man kept thinking clearly into his late 60s, outlasting the disease’s expected timeline by more than two decades.
When researchers sequenced his genome, they found a variant in a single gene, reelin, that appeared to explain his extraordinary resilience. That discovery, published in 2023, has since catalyzed a wave of research into whether activating one protein can switch on the brain’s built-in cleanup system and force it to dissolve the amyloid plaques that define Alzheimer’s disease. As of mid-2026, no reelin-targeted drug has reached clinical trials, but converging findings from multiple labs are building a case that the brain’s own immune cells can be reprogrammed to do what no medication has fully achieved.
The man who defied his DNA
The case was documented in Nature Medicine by a team led by neurologist Francisco Lopera at the University of Antioquia and researchers at Harvard and the Banner Alzheimer’s Institute. The patient carried a heterozygous variant called RELN-COLBOS (H3447R). Despite harboring the same PSEN1-E280A mutation that devastates his relatives, he showed only minimal cognitive decline late in life, far beyond what anyone with his genetic profile had ever experienced.
He was not the first resilience case in this kindred. In 2019, a woman from the same family was found to carry two copies of a rare APOE3 variant called Christchurch, which also delayed her symptoms by decades. But the reelin case was different in a critical way: the man had only one copy of the protective variant, suggesting that even a partial boost to reelin signaling might be enough to hold off the disease. That distinction matters for drug development, because it implies a therapy would not need to perfectly replicate the protein’s full effect to be useful.
As Nature’s news coverage noted at the time, a single patient cannot prove a general treatment principle. The man eventually did develop mild cognitive symptoms before his death, and his autopsy revealed substantial amyloid plaque buildup in his brain, meaning the variant did not prevent plaque formation. What it appeared to do was protect his neurons from the damage those plaques normally cause, keeping his synapses functional and his cognition intact far longer than expected.
How the brain’s cleanup crew actually works
To understand why reelin matters, it helps to know what normally goes wrong. The brain has its own immune cells called microglia, which are supposed to patrol for debris, surround amyloid plaques, and break them down. In Alzheimer’s patients, this system fails. Microglia become sluggish, inflamed, and unable to digest the waste they encounter. Plaques accumulate. Neurons die.
A study published in Nature Neuroscience showed that the FDA-approved antibody lecanemab works, at least in part, by reactivating this stalled cleanup program inside microglia. Using single-cell gene expression analysis, the researchers mapped how lecanemab shifts microglia into an active state: ramping up genes involved in engulfing plaques, breaking them down in lysosomes (the cell’s digestive compartments), and maintaining the energy supply needed to sustain that effort. The drug does not just tag plaques for removal. It reprograms the cell’s internal machinery to process amyloid at the molecular level.
That finding matters because it shows the microglial cleanup system is not permanently broken in Alzheimer’s. It can be switched back on. The question is whether reelin signaling taps into the same switch.
Why some brains cannot take out the trash
Two additional studies help explain why the cleanup system fails in the first place, and both point to a master regulator called TFEB, a protein that controls the genes responsible for autophagy, the cell’s process for digesting and recycling its own waste.
Research published in Communications Biology found that ApoE4, the most common genetic risk factor for sporadic Alzheimer’s, directly interferes with TFEB. The ApoE4 protein competes with TFEB for access to specific stretches of DNA that control lysosomal and autophagy genes. When ApoE4 wins that competition, the genes stay silent, and the cell loses its ability to break down accumulated proteins. The same study identified small molecules capable of restoring TFEB activity in ApoE4-affected cells, rescuing their waste-disposal function in laboratory experiments.
A related paper in Nature Cell Biology showed that autophagy is not just helpful for microglial function; it is essential. When autophagy works, microglia stay mobile and aggressive, surrounding plaques and pulling amyloid inside for destruction. When autophagy is impaired, microglia accumulate damaged internal structures, stop moving toward plaques, and enter a senescent state where they pump out inflammatory signals instead of clearing debris.
Together, these findings sketch a picture of Alzheimer’s as partly a waste-management crisis. The brain has the machinery to handle amyloid, but genetic and molecular factors can disable that machinery at multiple points. Reelin, TFEB, and microglial autophagy all appear to sit along the same general axis of cellular housekeeping, though researchers have not yet proven they form a single, connected pathway.
The gaps that remain
No one has directly tested whether activating reelin signaling triggers TFEB-driven autophagy in human brain tissue. The connection between the Colombian man’s protective variant and the microglial cleanup pathways described in the lecanemab and autophagy studies is an inference drawn from parallel findings, not a demonstrated chain of cause and effect.
There is also a fundamental question of scope. The PSEN1-E280A mutation causes autosomal dominant Alzheimer’s, which accounts for less than 1% of all cases. The vast majority of Alzheimer’s disease is sporadic, shaped by dozens of genetic risk factors, vascular health, metabolic conditions, and lifestyle. Whether boosting reelin would help someone whose disease is driven by ApoE4 and aging rather than a single dominant mutation is unknown.
Safety is another open concern. Reelin plays roles in brain development and adult synaptic function. Altering its signaling in older adults could carry risks for seizure susceptibility, neuronal circuit stability, or neuropsychiatric side effects that no study has yet characterized. Pushing microglia into a chronically activated state could also backfire, potentially damaging healthy synapses through excessive inflammation. Researchers have not yet defined a therapeutic window where the benefits of enhanced clearance outweigh these risks.
And the practical hurdles are significant. No reelin-activating drug exists in clinical development as of mid-2026. Moving from a genetic observation in one patient to a testable therapy requires identifying druggable targets within the reelin signaling cascade, demonstrating efficacy in animal models that faithfully represent human microglial biology, and designing trials that can measure both plaque clearance and cognitive outcomes over years.
What one man’s genome tells us about what comes next
The Colombian case is best understood not as a ready-made treatment blueprint but as a biological proof of concept. One person’s genome demonstrated that modifying a single node in a signaling network can dramatically alter the trajectory of an otherwise devastating disease. Independent research on lecanemab, TFEB, and microglial autophagy has since confirmed that the brain’s internal cleanup systems are real, targetable, and capable of being reactivated.
The convergence of these findings is what makes the current moment significant. Five years ago, the dominant strategy in Alzheimer’s research was to attack plaques from the outside, using antibodies to bind and remove amyloid. That approach has produced modest clinical results with drugs like lecanemab and donanemab. The reelin discovery suggests a complementary strategy: instead of only sending in external agents, find ways to rearm the brain’s own defenses.
Future work will likely combine genetic insight with precise imaging of amyloid and tau, single-cell profiling of microglia in living patients, and patient-derived organoid models that can test whether reelin activation and TFEB modulation work together. The story written in one man’s DNA has given researchers a compass heading. Turning it into a therapy that works for millions will require years of careful science, but the direction, for the first time, looks concrete.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
